Immunologic Monitoring and Cellular Products Laboratory

文摘：免疫监测和细胞产品实验室 免疫监测和细胞产品实验室(IMCPL)的目标是支持 发展癌症的细胞、病毒或基因疗法并监测对这些疗法的免疫学反应 在希尔曼癌症中心(HCC)注册的临床试验专利中的疗法。IMCPL是一个独特的设施 为肝细胞癌调查人员提供一整套最先进的技术和分析方法 各种生物疗法的临床试验，并监测对这些疗法的免疫反应。IMCPL还支持 未来转化为临床试验的临床前开发项目。IMCPL由特蕾莎·怀特赛德博士领导， (CII)在位于肝细胞癌研究展馆内的设施中监督20 FTE的工作人员。服务包括 由CLIA/CAP认证实验室中训练有素的人员提供，并有独立的质量保证(QA) 疏忽。IMCPL主要支持临床和翻译CII和CT研究项目。在2019财年， IMCPL为35名肝细胞癌成员(87%的使用率)提供了62项独立临床试验/研究方案，全部 与为癌症患者提供新的免疫疗法驱动的临床试验这一肝细胞癌使命相关。在.期间 在下一个项目期间，IMCPL将增加9个新的洁净室，从而扩大治疗细胞的生产能力和 计划在未来增加用于治疗的细胞产品的曲目。它还在升级其监测 分析单细胞和外体分子图谱的能力。

Abstract: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) The goals of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) are to support the development of cellular, viral or gene therapies for cancer and monitor immunological responses to these therapies in patents enrolled in clinical trials at the Hillman Cancer Center (HCC). IMCPL is a unique facility offering a comprehensive set of state-of-the-art technologies and assays to the HCC investigators conducting clinical trials with various biotherapies and monitoring immune responses to these therapies. IMCPL also supports pre-clinical developmental projects for future translation to clinical trials. IMCPL is led by Dr. Theresa Whiteside, (CII) who oversees a staff of 20 FTE in the facility located within the HCC Research Pavilion. Services are provided by trained personnel in a CLIA/CAP certified laboratory with independent quality assurance (QA) oversight. IMCPL primarily supports the clinical and translational CII and CT research programs. In FY2019, the IMCPL serviced 62 independent clinical trials for 35 HCC members (87% of the usage)/research protocols, all relevant to the HCC mission of providing novel immunotherapy-driven clinical trials to cancer patients. During the next project period, IMCPL will add 9 new clean rooms, thus expanding therapeutic cell production capabilities and plans to increase the repertoire of cellular products for therapy in the future. It is also upgrading its monitoring capabilities to analyses of single-cell and exosome molecular profiles.